News Releases Keyword Search Year None20232022202120202019201820172016 Dec-13-2021 Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021 Dec-01-2021 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Nov-15-2021 Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting Nov-09-2021 Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference Nov-04-2021 Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results Nov-03-2021 Oncternal Therapeutics Joins Karolinska Institutet’s NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies Nov-02-2021 Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board Nov-01-2021 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Oct-29-2021 Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results Oct-05-2021 Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »